Skip to main content
Premium Trial:

Request an Annual Quote

Nicolas Barthelemy, Carlos Paya

Fluidigm said this week that it has appointed Nicolas Barthelemy and Carlos Paya to its board of directors. Barthelemy most recently served as president and CEO of molecular diagnostics firm Biotheranostics. He previously served as president of global commercial operations at Life Technologies and has also led the firm's cell systems division. He also serves on the board of directors of Repligen. Paya is president, CEO, and director of immunotherapy firm Immune Design. He formerly served as president of pharmaceutical firm Elan, and was VP of Lilly Research Laboratories.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.